Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/11/2011

SAN DIEGO, March 11, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and announced fourth quarter and full-year 2010 financial results.

"With approximately $160 million in cash as of the end of February, we are in an excellent financial position," commented Barry D. Quart, PharmD, Ardea's president and chief executive officer.  "In addition, we recently reported positive, topline results from our Phase 2b study of lesinurad, previously called RDEA594, in gout patients not responding adequately to allopurinol alone.  These results support our view that lesinurad has the potential to significantly improve the lives of millions of gout patients who are untreated or inadequately treated due to the limitations of current therapies.  In the months to come, we expect to meet with the FDA to finalize the design of our Phase 3 program for lesinurad."

Recent Accomplishments and Important Upcoming Events

  • In December 2010, the United States Adopted Names Counsel (USAN) adopted lesinurad, pronounced "le sin' ure ad", as the USAN name for RDEA594.
  • In January 2011, we announced positive, topline results from a Phase 2b study (Study 203) adding lesinurad to allopurinol in 208 allopurinol-refractory patients. At the highest lesinurad dose tested in this study, the number of patients taking the combination who achieved the medically recommended target of below 6 mg/dL was more than three times the number of patients who achieved the target on allopurinol alone.  This translated into an overall response rate of 89 percent using a "last observation carried forward", or LOCF, analysis.  The combination of lesinurad and allopurinol was also well tolerated.
  • In Februar
    '/>"/>

  • SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
    2. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
    3. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
    4. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
    5. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
    6. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
    7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    8. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    9. Ardea Biosciences to Present at Two Upcoming Investor Conferences
    10. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
    11. Ardea Biosciences Prices Public Offering of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... Aug. 28, 2014   SunTrust Robinson Humphrey ... veterans to its equity research team in biotechnology ... expansion in equity research demonstrates our commitment to ... to enhance their investment decision making," said ... "We continue to make significant investments in differentiated ...
    (Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
    (Date:8/28/2014)... Washington, USA (PRWEB) August 27, 2014 ... next month for SPIE Laser Damage 2014 ... optical materials for high-power lasers will run 14-17 September. ... society for optics and photonics . , The premier ... for understanding laser damage to optical materials will engage ...
    (Date:8/28/2014)... 2014 Earlier this month, a ... partnership with the U.S. Air Force on the performance ... indicated that this type of fuel made from mustard ... be important to America’s Eco friendly future. In fact, ... mandate to become independent of foreign oil over the ...
    Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
    ... Software Inc., the leading,provider of web-based employee ... independent research firm Bersin & Associates ranked,Halogen ... its recent report on talent,management vendors. Halogen ... product strength, architecture and customer satisfaction., ...
    ... BioSeek, Inc. today,announced that Roy A. Whitfield ... of directors. Mr. Whitfield had joined BioSeek,s board ... the Company since November,2005., "Roy,s management experience ... been extraordinarily valuable to BioSeek thus,far. We look ...
    ... - Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ONY), a biotechnology ... for the treatment of cancer, today,announced the launch ... ., "We are excited about our new ... which provides additional information about our,product pipeline and ...
    Cached Biology Technology:Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction 2BioSeek Elects Roy Whitfield Executive Chairman of Board of Directors 2
    (Date:8/31/2014)... is available in French . ... just published in the prestigious Nature Neuroscience journal ... Centre of the Douglas Mental Health University Institute and McGill ... circuitry and dynamic mechanisms controlling memory as well of the ... sub-region named the subiculum. , In 2009, they developed ...
    (Date:8/29/2014)... Until recently, little has been known about what ... international team of scientists, one of whom is a ... by showing that genes controlling the development of the ... rabbit domestication., The study was published Aug. 28 in ... questions. It is online at http://www.sciencemag.org/ ., The ...
    (Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
    Breaking Biology News(10 mins):Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Assortativity signatures of transcription factor networks contribute to robustness 2
    ... map data into BiblioSphere , Genomatix Software GmbH ... Science (AAAS) today announced an agreement that allows ... Environment into Genomatix's BibliospherePE pathway knowledge base and ... journal Science, developed the Signal Transduction Knowledge Environment, ...
    ... of a protein, human CD38, which may lead to important ... in almost every cellular process. The findings also may offer ... to diabetes and HIV-AIDS. , Levels of the ... human CD38 a marker for these diseases. , As ...
    ... at the National Institute of Child Health and Human ... parasite disperses from the red blood cells it infects. ... Development is one of the Institutes comprising the National ... September 20 Current Biology. , "This discovery provides the ...
    Cached Biology News:Genomatix, AAAS ink agreement 2Protein structure key for AIDS, cell function 2Researchers discover how malaria parasite disperses from red blood cells 2Researchers discover how malaria parasite disperses from red blood cells 3
    ... cyclin required for G1-phase progression and is ... cyclin D2 can phosphorylate pRB when associated ... Human, Mouse, and Rat. Others-not tested. ... suited for neutralization of cyclin D2 activity ...
    Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
    ... Synthetic peptide corresponding ... Antigen Family: ... Antigen Subfamily: not ... Recommended Storage: Long ...
    V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
    Biology Products: